title: Omega-3 Fatty Acid-Rich Parenteral Nutrition: Is It a Double-Edged Sword?
abstract: Parenteral nutrition (PN) has been strongly associated with intestinal failure-associated liver disease. Cholestasis, liver steatosis, and liver fibrosis are features of this liver injury, which can progress to end stage liver disease. Omega-3 fatty acid rich PN has been shown to alleviate cholestasis and steatosis. There have been reports although suggesting that it may not be able to arrest or reverse the progression to liver fibrosis. In this article, we develop a hypothesis of the mechanism of how Ω-3 fatty acid rich PN may influence the progression of fibrosis.
authors.affiliation: Paediatric Liver, GI and Nutrition Centre, King's College Hospital, London, UK.
authors.forename: Eirini
authors.initials: E
authors.lastname: Kyrana
authors.forename: Anil
authors.initials: A
authors.lastname: Dhawan
mesh_terms: D000818:Animals; D002780:Cholestasis, Intrahepatic / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control; D051048:Diacylglycerol O-Acyltransferase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D005217:Fat Emulsions, Intravenous / Q000009:adverse effects* / Q000378:metabolism; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage / Q000009:adverse effects* / Q000378:metabolism; D006801:Humans; D008099:Liver / Q000201:enzymology / Q000378:metabolism; D008103:Liver Cirrhosis / Q000201:enzymology / Q000209:etiology* / Q000378:metabolism; D008954:Models, Biological; D065626:Non-alcoholic Fatty Liver Disease / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control*; D010288:Parenteral Nutrition / Q000009:adverse effects*; D014280:Triglycerides / Q000378:metabolism
chemical_list: D005217:Fat Emulsions, Intravenous; D015525:Fatty Acids, Omega-3; D014280:Triglycerides; D051048:Diacylglycerol O-Acyltransferase